Abstract Details

Title Outcomes with GLP-1RAs in Idiopathic Intracranial Hypertension: A Systematic Review and Meta-analysis.

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) S20 - Innovations in Cerebrovascular Therapy (4:42 PM-4:54 PM)

Poster/Presentation
Number 007

Objective To evaluate the efficacy of GLP-1 receptor agonists (GLP-1 RAs) on weight management, headache frequency, and visual outcomes in patients with idiopathic intracranial hypertension (IIH).

Background IIH, predominantly affecting young obese women, is presented clinically in chronic headaches, papilledema, and risk of visual loss. Giving the emerging evidence of GLP-1RAs in managing weight and the strong association between IIH and obesity, their therapeutic potential in IIH require systemic evaluation.

Design/Methods This systematic review adhered to PRISMA guidelines and is prospectively registered to PROSPERO. We searched PubMed, Scopus, Embase, and Web of Science through June 2025 using terms related to IIH and GLP-1 RAs. Observational and randomized controlled studies evaluating GLP-1 RAs in adults with diagnosed IIH were included. Primary outcomes were BMI change, headache frequency, and visual parameters. Meta-analysis was performed using STATA with mean differences and 95% confidence intervals.

Results We included a total of seven studies with 12,200 patients for analysis. In comparison with the control group, BMI and monthly headache days were significantly reduced by GLP 1RAs (MD: –0.98 kg/m2; 95% CI: [–1.38 to –0.57], p-value < 0.001), (MD: –3.45 days; 95% CI:[–5.57 to –1.50], p-value < 0.001) respectively. Visual acuity at 6 months showed a significant improvement (MD: 0.10; 95% CI: [0.02 to 0.18], p-value = 0.02), while visual field reduction was significantly less in the GLP-1 RA group (MD: -1.95; 95% CI: -3.32 to -0.58, p=0.01). We observed no significant differences in peripapillary retinal nerve fiber layer thickness or Frisén scale changes.

Conclusions GLP-1RAs showed promising effects in patients with IIH through weight and headache frequency reduction. The long-term visual effects were promising through higher visual acuity and a good visual field. Large-scale studies are needed for a better understanding of the effects of GLP-1RAs in IIH.

Authors/Disclosures
Mohamed S. Saad, MD PRESENTER	Dr. Saad has nothing to disclose.
Basma Kamel	Basma Kamel has nothing to disclose.
Noha S. Shaban	Dr. Shaban has nothing to disclose.
Shree Rath, MBBS	Miss Rath has nothing to disclose.
Iman M. Alhnfi, MBBS	Dr. Alhnfi has nothing to disclose.
sohaila m. mohamed, MBBS	Dr. mohamed has nothing to disclose.
Omnia Samy El-Sayed, MD	Dr. Samy El-Sayed has nothing to disclose.
Mona Ali, PhD	Dr. Ali has nothing to disclose.

��ɫ��

��ɫ��